Go to Page # Page of 24

Pharmaceutical and Biotechnology R&D: Technological Performance Implications

 Jongwook Kim
Description: Why biotechnology alliances?:- It is difficult to measure alliance performance, particularly in R&D alliances. Biotechnology alliances provides an empirical context where a fairly objective indicator of alliance performance exists: Because of FDA regulations, information about intermediate stages in drug development are made public.Biotechnology industry:- Small biotechnology R&D firms usually have capabilities in product R&D activities (upstream activities). Larger pharmaceutical firms (and some established biotechnology firms) supply capabilities in commercialization activities (downstream activities, i.e., manage the regulatory process, large-scale manufacturing, marketing & distribution, etc.).
Views: 764
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: KLIC
 ‐ More of their Presentations
Pharmaceutical-Biotechnology R&D:
Technological Performance Implications

Western Washington University
College of Business and Economics

Introduction: Research question

How do different governance mechanisms – both formal
and informal – impact alliance performance?

How do formal governance mechanisms that seek to
mitigate informat ... See more

Recent Presentations

22 March, 2018

Pharma 2020: The vision

Demand for effective medicines is rising, as the population ages, new medical needs emerge and the disease burden of the developing world increasingly resembles that of the develop

21 March, 2018

Management of hypertension

NICE Pathways bring together everything NICE says on a topic in an interactive flowchart. NICE Pathways are interactive and designed to be used online.

20 March, 2018